BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Endocrine gland cancer AND SSX1, MGC5162, 6756, ENSG00000126752, RP11-552E4_1, SSRC, MGC150425, Q16384
95094 results:

  • 1. Active surveillance is a feasible and safe strategy in selected patients with papillary thyroid cancer and suspicious cervical lymph nodes detected after thyroidectomy.
    Solórzano M; Lustig N; Mosso L; Espinoza M; Santana R; Gonzalez H; Montero PH; Cruz F; Solar A; Domínguez JM
    Arch Endocrinol Metab; 2024 May; 68():e230146. PubMed ID: 38709151
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Epidemiological profile of neuroendocrine tumors in adults in Brazil.
    Brunelli Pujatti P; Paim V; Gonçalves R; Vilhena B; Bergmann A; Santos Thuler LC; Bulzico D
    Arch Endocrinol Metab; 2024 May; 68():e230013. PubMed ID: 38709149
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Identification and Economic Evaluation of Differentiated Thyroid cancer Care Consumption Patterns Using Sequence Analysis.
    Demeulemeester R; Grosclaude P; Grunenwald S; Saint-Pierre P; Savy N; Costa N
    Int J Public Health; 2024; 69():1606664. PubMed ID: 38707870
    [No Abstract]    [Full Text] [Related]  

  • 4. The prophylactic antiemetic therapies in management of differentiated thyroid cancer patients with radioactive iodine therapy: a single-center, non-randomized clinical trial.
    Li X; Cao J; Wang W; Zhu X; Sun Y; Song L; Zhang W; Han Y
    Front Endocrinol (Lausanne); 2024; 15():1310223. PubMed ID: 38706697
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. piR-1919609 Is an Ideal Potential Target for Reversing Platinum Resistance in Ovarian cancer.
    Yan Y; Tian D; Zhao B; Li Z; Huang Z; Li K; Chen X; Zhou L; Feng Y; Yang Z
    Technol Cancer Res Treat; 2024; 23():15330338241249692. PubMed ID: 38706262
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Perioperative management of a patient with unexpectedly detected early-stage ovarian mucinous carcinoma combined with progressive bulbar paralysis: a case report and literature review.
    Zhang D; Xu R; Huo T; Liu Y; Hao Z; Sun Y; Xi X; Du X; Wang L; Du J
    BMC Womens Health; 2024 May; 24(1):274. PubMed ID: 38704534
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Smoking history is associated with reduced efficacy of neoadjuvant therapy in pancreatic adenocarcinoma.
    Akumuo RC; Reddy SP; Westwood C; Devarajan K; Barrak D; Reddy SS; Villano AM
    J Gastrointest Surg; 2024 May; 28(5):605-610. PubMed ID: 38704197
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial.
    Belotte J; Felicetti B; Baines AJ; YoussefAgha A; Rojas-Espaillat L; Ortiz AG; Provencher D; Vázquez RM; Cortijo LG; Zeng X
    Trials; 2024 May; 25(1):301. PubMed ID: 38702828
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Factors influencing TSH suppression efficacy in postoperative papillary thyroid carcinoma patients: a retrospective cohort study.
    Zhang Q; Zhong ZZ; Wu T; He YQ
    BMC Surg; 2024 May; 24(1):133. PubMed ID: 38702652
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Predictors of Blood Transfusion in Patients Undergoing Cytoreductive Surgeries for Ovarian Malignancy.
    Pearce JV; Zhao J; Randall L; Sullivan SA; Miller D; Tossas K
    South Med J; 2024 May; 117(5):266-271. PubMed ID: 38701848
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of recurrent ovarian cancer: A systematic review and meta-analysis.
    Chen Y; Liu X; Hu Y; Xia L
    Medicine (Baltimore); 2024 May; 103(18):e38019. PubMed ID: 38701316
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Nongestational ovarian choriocarcinoma with bilateral teratoma: A rare case report and literature review.
    Ao X; Hu S; Tan S; Xiong W
    Medicine (Baltimore); 2024 May; 103(18):e36996. PubMed ID: 38701311
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Incidentally detected follicular thyroid carcinoma mimicking parathyroid adenoma on Tc-99m MIBI scan: A case report.
    Han YH; Jeong HJ; Lee SY; Lim ST
    Medicine (Baltimore); 2024 May; 103(18):e38107. PubMed ID: 38701245
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. OTUB2 silencing promotes ovarian cancer via mitochondrial metabolic reprogramming and can be synthetically targeted by CA9 inhibition.
    Nan Y; Wu X; Luo Q; Chang W; Zhao P; Zhang L; Liu Z
    Proc Natl Acad Sci U S A; 2024 May; 121(19):e2315348121. PubMed ID: 38701117
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Score based on contrast-enhanced ultrasound predict central lymph node metastasis in papillary thyroid cancer.
    He L; Chen X; Hu J; Meng Y; Zhang Y; Chen W; Fan Y; Li T; Fang J
    Front Endocrinol (Lausanne); 2024; 15():1336787. PubMed ID: 38699389
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Analysis of chemoresistance characteristics and prognostic relevance of postoperative gemcitabine adjuvant chemotherapy in pancreatic cancer.
    Ren J; Wu S; Su T; Ding J; Chen F; Li J; Wang Z; Han L; Wu Z
    Cancer Med; 2024 May; 13(9):e7229. PubMed ID: 38698688
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Feasibility and safety of modified en-bloc resection in endoscopic thyroid surgery via bilateral areolar approach - long-term institutional analysis ten years after surgery.
    Xie Q; Ma J; Du Y; Liu L; Zhu R; Liu D; Wang P; Yu X
    Front Endocrinol (Lausanne); 2024; 15():1302510. PubMed ID: 38694946
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. A novel method of tunneling retroperitoneoscopic adrenalectomy: a prospective study.
    Zhang P; Pei Y; Zhi Y; Sun F
    BMC Urol; 2024 Apr; 24(1):101. PubMed ID: 38689249
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Antitumor activity of extracellular signal-regulated kinases 1/2 inhibitor BVD-523 (ulixertinib) on thyroid cancer cells.
    Chen Y; Xiao X; Hu G; Liu R; Xue J
    J Cancer Res Ther; 2024 Apr; 20(2):570-577. PubMed ID: 38687926
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model.
    Dutta D; Ray P; De A; Ghosh A; Hazra RS; Ghosh P; Banerjee S; Diaz FJ; Upadhyay SP; Quadir M; Banerjee SK
    PLoS One; 2024; 19(4):e0297749. PubMed ID: 38687749
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 4755.